Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
The aim of the funding regime is to direct funding on the basis of need and the cost of provision to meet those needs. Schools were expected to fund the first £10,000 of provision from their own resources before additional funding would be received from the local authority. Recent newspaper reports suggest the regime may negatively impact schools where the school has embraced inclusion and have a number of pupils with SEN statements as the £10,000 per pupil expectation would still apply. The consequence is that the general support for other children with needs is reduced as schools struggle to fill the funding gap.
Clearly, this was not the intention of the funding changes and greater clarity is required from the DfE to local authorities and schools on the relationship between the funding streams. Without that clarity, schools may need to make changes to staffing given the reduced funding and pupils will lose out on support. Overall, the Government’s key policy of closing the gap in attainment will also fail if support is not made available to those who need it.
With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.
View blog
The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.
Our top tips for supporting transgender and non-binary pupils.
On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.
Partner
Select which mailings you would like to receive from us.
Sign up